Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Pre-Treatment Hemoglobin Concentration and Absolute Monocyte Count as Independent Prognostic Factors for Survival in Localized or Locally Advanced Prostate Cancer Patients undergoing Radiotherapy

Version 1 : Received: 15 September 2022 / Approved: 16 September 2022 / Online: 16 September 2022 (10:11:15 CEST)

A peer-reviewed article of this Preprint also exists.

Magrowski, Ł.; Masri, O.; Ciepał, J.; Depowska, G.; Nowicka, Z.; Stando, R.; Chimiak, K.; Bylica, G.; Czapla, B.; Masri, M.; Cichur, F.; Jabłońska, I.; Gmerek, M.; Wojcieszek, P.; Krzysztofiak, T.; Sadowski, J.; Suwiński, R.; Rajwa, P.; Moll, M.; Goldner, G.; Majewski, W.; Miszczyk, M. Pre-Treatment Hemoglobin Concentration and Absolute Monocyte Count as Independent Prognostic Factors for Survival in Localized or Locally Advanced Prostate Cancer Patients Undergoing Radiotherapy. Biomedicines 2022, 10, 2514. Magrowski, Ł.; Masri, O.; Ciepał, J.; Depowska, G.; Nowicka, Z.; Stando, R.; Chimiak, K.; Bylica, G.; Czapla, B.; Masri, M.; Cichur, F.; Jabłońska, I.; Gmerek, M.; Wojcieszek, P.; Krzysztofiak, T.; Sadowski, J.; Suwiński, R.; Rajwa, P.; Moll, M.; Goldner, G.; Majewski, W.; Miszczyk, M. Pre-Treatment Hemoglobin Concentration and Absolute Monocyte Count as Independent Prognostic Factors for Survival in Localized or Locally Advanced Prostate Cancer Patients Undergoing Radiotherapy. Biomedicines 2022, 10, 2514.

Abstract

The prognostic value of inflammatory indices such as absolute monocyte count (AMC) has been a subject of interest in recent prostate cancer (PCa) literature, while hemoglobin concentration (HGB) has been recognized as a survival factor in castration-resistant metastatic prostate cancer, but its value remains unclear in localized disease. The aim of this study was to test the prognostic value of these two simple and inexpensive biomarkers for survival based on a cohort of 1016 patients treated with primary radiotherapy and androgen deprivation therapy for localized or locally advanced intermediate- or high-risk PCa. Complete survival data was available for all cases based on the National Cancer Registry with a median observation time of 120 months (IQR 80.9-144.7). Missing blood test data were supplemented using the Nearest Neighbor Imputation, and the Cox proportional hazards regression model was used for analysis. The median age was 68.8 years (IQR 63.3-73.5). The five-year overall survival was 82.8%, and 508 patients were alive at the time of analysis. The median time between blood tests and the first day of radiotherapy was 6 days (IQR 0-19). HGB (p = 0.009) and AMC (p = 0.003) were independent prognostic factors for survival, along with age, ISUP Grade Group, clinical T stage and maximum PSA concentration. The study demonstrated that HGB and AMC can be useful biomarkers for overall survival in patients treated with radiotherapy for localized intermediate- or high-risk PCa.

Keywords

hemoglobin; monocytes; overall survival; prostate cancer; radiotherapy

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.